For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

News [1770]

COVID-19 and cancer: Useful resources

COVID-19 and cancer: Useful resources

FDA approves brigatinib for ALK-positive metastatic NSCLC

FDA approves brigatinib for ALK-positive metastatic NSCLC

Molecular testing rates for lung cancer in most countries less than 50 percent

Molecular testing rates for lung cancer in most countries less than 50 percent

ASCO 2020: Durvalumab added to standard chemotherapy improved overall survival in mesothelioma

ASCO 2020: Durvalumab added to standard chemotherapy improved overall survival in mesothelioma

FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression

FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression

FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumour expression ≥1%)

FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumour expression ≥1%)

Treatment guidance for lung cancer patients during the COVID-19 pandemic

Treatment guidance for lung cancer patients during the COVID-19 pandemic

ASCO 2020: Trial confirms durable and long-term survival benefit for nivolumab plus ipilimumab over chemotherapy in metastatic first-line non-small cell lung cancer patients

ASCO 2020: Trial confirms durable and long-term survival benefit for nivolumab plus ipilimumab over ...

FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions

FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer

More from ecancer